Anxiogenic properties of an inverse agonist selective for α 3 subunit‐containing GABAA receptors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
α 3IA (6‐(4‐pyridyl)‐5‐(4‐methoxyphenyl)‐3‐carbomethoxy‐1‐methyl‐1 H‐pyridin‐2‐one) is a pyridone with higher binding and functional affinity and greater inverse agonist efficacy for GABA A receptors containing an α 3 rather than an α 1, α 2 or α 5 subunit. If doses are selected that minimise the occupancy at these latter subtypes, then the in vivo effects of α 3IA are most probably mediated by the α 3 subtype. α 3IA has good CNS penetration in rats and mice as measured using a [3 H]Ro 15‐1788 in vivo binding assay. At doses in rats that produce relatively low levels of occupancy (12%) in the cerebellum (i.e. α 1‐containing receptors), α 3IA (30 mg kg−1 i.p.), like the nonselective partial inverse agonist N‐methyl‐β‐carboline‐3‐carboxamide (FG 7142), not only caused behavioural disruption in an operant, chain‐pulling assay but was also anxiogenic in the elevated plus maze, an anxiogenic‐like effect that could be blocked with the benzodiazepine antagonist Ro 15‐1788 (flumazenil). Neurochemically, α 3IA (30 mg kg−1 i.p.) as well as FG 7142 (15 mg kg−1 i.p.) increased the concentration of the dopamine metabolite 3,4‐dihydroxyphenylacetic acid in rat medial prefrontal cortex by 74 and 68%, respectively, relative to vehicle‐treated animals, a response that mimicked that seen following immobilisation stress. Taken together, these data demonstrate that an inverse agonist selective for GABA A receptors containing an α 3 subunit is anxiogenic, and suggest that since α 3‐containing GABA A receptors play a role in anxiety, then agonists selective for this subtype should be anxiolytic. British Journal of Pharmacology (2005) 144, 357–366. doi:10.1038/sj.bjp.0706056
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
The amygdala: vigilance and emotion
Davis, M., & Whalen, P. J. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000812 · Cited by 2,882
Which GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Self-citationBenzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · cited 3×
“…diazepam-insensitive a2 or a3 GABAA populations suggests that the a3 subtype does not mediate the anxiolytic effects of diazepam, whereas a2 does (Löw et al., 2000), the interpretation of these behavioural data is confounded by methodological issues (Crestani et al., 2000b; Reynolds et al.,…”
BackgroundMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Self-citationRole of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety
Walker, D. L., Toufexis, D. J., & Davis, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01282-2 · Cited by 838
Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 2×
“…by L-655708 may not be due to the a5 subtype is consistent with observations that there is no alteration in the anxiety levels of a5 knockout mice (Collinson et al., 2002), and that a compound with inverse agonist efficacy selective for the a5 subtype is not anxiogenic (Sternfeld et al., 2004).”
BackgroundSelf-citationTrace fear conditioning involves hippocampal α 5 GABA A receptors
Crestani, F., Keist, R., Fritschy, J.-M., Benke, D., Vogt, K., Prut, L., Blüthmann, H., Möhler, H., & Rudolph, U. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142288699 · Cited by 528
Chapter 19 The determinants of stress-induced activation of the prefrontal cortical dopamine system
(1991) · Progress in Brain Research · doi:10.1016/s0079-6123(08)62691-6 · Cited by 364 · cited 3×
“In the present study, we chose DOPAC as a marker of dopamine turnover since it has been shown to be a reliable marker of stress- induced activation of the dopamine system in the prefrontal cortex (Deutch & Roth, 1990).”
BackgroundMethod
Cited by
GABAA receptors: Subtypes provide diversity of function and pharmacology
Olsen, R. W., & Sieghart, W. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.045 · Cited by 982
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
Role of GABA in anxiety and depression
Kalueff, A. V., & Nutt, D. J. (2007) · Depression and Anxiety · doi:10.1002/da.20262 · Cited by 534
Sleep and anxiety: From mechanisms to interventions
Chellappa, S. L., & Aeschbach, D. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101583 · Cited by 509
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499
GABAA receptor diversity and pharmacology
Möhler, H. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0284-3 · Cited by 363
Structure, Pharmacology, and Function of GABAA Receptor Subtypes
Sieghart, W. (2006) · Advances in Pharmacology · doi:10.1016/s1054-3589(06)54010-4 · Cited by 317
Dias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247
“…of BZs (Rudolph et al., 1999; McKernan et al., 2000) and the 5 subtype plays a role in aspects of cognition (Collinson et al., 2002; Crestani et al., 2002), there remains controversy over which of the subtypes, 2 versus 3, is associated with anxiolysis (Low et al., 2000; Atack et al., 2005).”
BackgroundMethodInfluentialSelf-citationAn Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
Dawson, G. R., Maubach, K. A., Collinson, N., Cobain, M., Everitt, B. J., MacLeod, A. M., Choudhury, H. I., McDonald, L. M., Pillai, G., Rycroft, W., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092320 · Cited by 241
Self-citationRowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212
Self-citationVictorri‐Vigneau, C., Dailly, E., Veyrac, G., & Jolliet, P. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02861.x · Cited by 201
Atack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188
Self-citationSearching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163
“Alpha 3-selective inverse agonism is anxiogenic in mice (Atack et al., 2005), whereas selective alpha 3 agonism is anxiolytic in mice and primates (Dias et al.”
BackgroundAli, A. B., & Thomson, A. M. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm160 · Cited by 129
de Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84
“The anxiolytic effect of benzodiazepines is thought to be mediated by GABAA 2 receptors (Low et al., 2000; Rudolph et al., 2001), although more recently more emphasis is given to GABAA 3 (Atack et al., 2005; Atack, 2005; Dias et al., 2005).”
BackgroundRole of GABAA receptors in cognition
Möhler, H. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371328 · Cited by 79
Cheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66
“31 Although α 3IA’s weak inverse efficacy at α 2 subtype could be argued to be anxiogenic, novel non-benzodiazepine compounds such as adipiplon (NG2-73) and SB-205,384 produced anxiolytic effects without any efficacy at the α 2 subtype.”
Ali, A. B. (2007) · Journal of Neurophysiology · doi:10.1152/jn.00156.2007 · Cited by 62
Behlke, L. M., Foster, R. A., Liu, J., Benke, D., Benham, R. S., Nathanson, A. J., Yee, B. K., Zeilhofer, H. U., Engin, E., & Rudolph, U. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.49 · Cited by 57
Tzanoulinou, S., García-Mompó, C., Castillo-Gómez, E., Veenit, V., Nacher, J., & Sandi, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094666 · Cited by 56
Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52
Self-citationAtack, J. R., Pike, A., Clarke, A., Cook, S. M., Sohal, B., McKernan, R. M., & Dawson, G. R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006973 · Cited by 23
“These data are consistent with observations in mice, which showed that the ID50 for [ 3H]L-655,708 binding was much lower than that for [3H]Ro 15-1788 binding to 1 or 2/ 3 receptors (respective ID50 values 0.2, 1.1, and 4 mg/kg) (Atack et al., 2005a).”
MethodResultSelf-citationPharmacological Properties of DOV 315,090, an ocinaplon metabolite
Berezhnoy, D., Gravielle, M. C., Downing, S., Kostakis, E., Basile, A. S., Skolnick, P., Gibbs, T. T., & Farb, D. H. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-11 · Cited by 18
Metadata
- Authors
- Atack, J. R., Hutson, P. H., Collinson, N., Marshall, G., Bentley, G., Moyes, C., Cook, S. M., Collins, I., Wafford, K., McKernan, R. M., & Dawson, G. R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 144
- Issue
- 3
- Pages
- 357-366
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2090116461
- Cited by
- 134
- References
- 10
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.